Relapsing-Remitting Multiple Sclerosis
Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis where patients experience flare-ups of symptoms followed by periods of remission, during which symptoms may improve or disappear.
Multiple Sclerosis: IMU-838 Treatment Study
We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 55 years old?
- Do you have relapsing-remitting multiple sclerosis (RRMS)?
- Are you currently pregnant or breastfeeding?
- Have you had an MS relapse in the last 30 days?
- Are you taking any medications that could affect your participation, like steroids or immunosuppressants?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Imu-838
Vidofludimus Calcium
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
Department of Neurology diseases
Blagoevgrad, Bulgaria
Multi-profile Hospital for Active Treatment Heart and Brain EAD
Department of Neurology diseases
Pleven, Bulgaria
University Multiprofile Hospital For Active Treatment Dr. Georgi Stranski EAD
Clinic of Neurology
Pleven, Bulgaria
Sponsor: Immunic AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.